Trials / Terminated
TerminatedNCT04803006
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-myeloablative Conditioning, for Tolerance Induction in Living Donor Renal Transplantation
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- ITB-Med LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor renal transplantation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | TCD601 | Investigational Product |
Timeline
- Start date
- 2023-01-17
- Primary completion
- 2025-10-30
- Completion
- 2025-10-30
- First posted
- 2021-03-17
- Last updated
- 2026-02-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04803006. Inclusion in this directory is not an endorsement.